Seeing cancer risk the biopsy missed: a tissue test adds a second set of eyes

Castle Biosciences will present three studies at the American College of Gastroenterology's 2026 meeting in Nashville on its TissueCypher test for Barrett's oesophagus, a precancerous condition. The test reads protein markers and tissue structure in a routine biopsy sample to estimate a person's five-year risk of progression — information that can differ from what standard pathology alone suggests. Researchers say that extra signal can help doctors match monitoring and treatment to each patient's actual risk.